© Reuters. FILE PHOTO: People, some wearing protective face masks, walk over Westminster Bridge, amid the coronavirus disease (COVID-19) pandemic, in London, Britain, July 4, 2021. REUTERS/Henry Nicholls/File Photo
LONDON (Reuters) – It is a long road back to business as usual from the COVID-19 pandemic, the head of Britain’s coronavirus genome sequencing effort told Reuters, adding she was on alert for new mutations to the Delta variant that is sweeping the world.
Prime Minister Boris Johnson has ended England’s coronavirus lockdown, saying Britain must cautiously learn to live with the virus, and that a quick vaccine rollout has allowed for a summer reopening.
Sharon Peacock, chair of the COVID-19 Genomics UK (COG-UK) consortium, said that the process of returning to normal would be slow, due to uneven vaccine rollouts globally.
“It’s quite a long path to get back to business as usual,” she told Reuters, adding that clear global surveillance for new variants and co-ordination on the best vaccine against what is coming up, as there is with flu, would be needed.
“I see that as quite a long journey. So it’s not going to be one day that we wake up and say right we’re going to live with COVID-19 and everything’s okay. I think there’s still a lot of groundwork to be done.”
Britain has launched a New Variant Assessment Platform Programme to share its genomics expertise globally.
The variant of biggest concern at the moment is the Delta variant, which Peacock characterises as the “fittest and fastest variant yet”.
Delta is highly transmissible and has also been shown to reduce the effectiveness of the first dose of COVID-19 vaccines, and could become even more troublesome.
“There’s quite a lot of new mutations in the Delta variant, and so that’s being watched very carefully. There’s no reason at this point in time to be alarmed about that,” she said.
“But we have to continue to watch for a particular sort of variant of a variant if you like, that is associated with, for example, even more spread… That’s under constant monitoring at the moment.”
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.